

Format for ANSWERING REVIEWERS



July 13, 2015

Dear Editor,

Please find enclosed the edited manuscript in Word format (file name: 18437-review.doc).

Title: Chronic hepatitis C virus infection and lipoprotein metabolism

Author: Yoshio Aizawa, Nobuyoshi Seki, Tomohisa Nagano, and Hiroshi Abe

Name of Journal: *World Journal of Gastroenterology*

ESPS Manuscript NO: 18437

The manuscript has been improved according to the suggestions of reviewers:

1 Format has been updated

Thank you for reviewing our manuscript.

2 Revision has been made according to the suggestions of the reviewer

(1) Thank you for reviewing our article. According to your suggestion, we clearly mentioned that HCV by itself can modulate lipid/lipoprotein metabolism in the section entitled 'clinical aspects of disturbed lipid/lipoprotein metabolism' (p18-p20). As the mechanisms how HCV/HCV-related hepatitis disturbs lipoprotein metabolism is very complex and unsolved issue, we could not illustrate this issue as Fig 5.

(2) Thank you for reviewing our article. According to your suggestion, we highlighted the significance of HMG-CoA reductase inhibitors (Statins) as adjuvant therapy against HCV infection. Moreover, we emphasized the significance of eicosapentaenoic acid on anti-HCV therapy (p12). We added the significance of proinflammatory cytokines on progression of atherosclerosis in p20. We believe that the upper part of Table 1 is readable in the new version of the manuscript. We correct the grammatical mistakes according to your suggestion.

(3) Thank you for reviewing our article. We partially agree with your opinion that our manuscript was somewhat confused. We added the section entitled 'clinical aspects of lipid/lipoprotein metabolism in patients with chronic hepatitis' (p18-p20). We adequately correct the topology of some sentences in order to avoid confusion. In addition, we try to concise the literature. We modify the part of HCV lifecycle and lipoprotein metabolism (the basic mechanism of lipid metabolism and HCV interaction), in the view point of possible targets for anti-HCV therapy. In addition, we discuss about the paper by Rojas A et al, published on *J Viral Hepat.* 2014 Jan;21(1):19-24 (p18-p19). The possible therapeutic aspect of lipid lowering drug in patients with HCV infection is added (p12). The clinical aspect of dyslipoproteinemia in patients with HCV related disease (chronic hepatitis, cirrhosis and hepatocellular carcinoma) may be discussed in our refined article, especially in the section of 'clinical aspects of lipid/lipoprotein metabolism in patients with chronic hepatitis' (p18-p20). We believe that we eliminate the confusion of our review article.

3 References and typesetting were corrected

Thank you again for publishing our manuscript in the *World Journal of Gastroenterology*.

Sincerely yours,

Yoshio Aizawa, MD, PhD, Professor

Department of Internal Medicine,

6-41-2 Aoto, Katsushika-ku 125-8506, Tokyo, Japan.

Email: aichanyoshi@yahoo.co.jp

Telephone: +83-33603-2111

Fax: +83-33838-9944